SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?


To: johnsto1 who wrote (31067)8/2/2000 11:43:18 AM
From: johnsto1  Respond to of 57584
 
GNSC is good value to the other genomics to come to market under $20

Aug 01 Genaissance Pharms GNSC 6M 11-13 13 15
Lead Underwriter: Deutsche Bc Alex. Br. Co-managers: Bear Stearns, Salomon Smth Brny, UBS Warburg
Description: Co's HAP Technology is used to examine haplotypes (units of genetic variation) in blood samples